Discovery of remogliflozin etabonate: A potent and highly selective SGLT2 inhibitor. (15th March 2021)

• Record Type: Journal Article
• Authors: Shimizu, Kazuo; Fujikura, Hideki; Fushimi, Nobuhiko; Nishimura, Toshihiro; Tatani, Kazuya; Katsuno, Kenji; Fujimori, Yoshikazu; Watanabe, Shinjiro; Hiratochi, Masahiro; Nakabayashi, Takeshi; Kamada, Noboru; Arakawa, Koichi; Hikawa, Hidemasa; Azumaya, Isao; Isaji, Masayuki
• Is Part Of: Bioorganic & medicinal chemistry. Volume 34(2021)
• Publication Date: 2021-03-15
• Subjects: Type 2 diabetes mellitus -- SGLT2 inhibitor -- O-glucoside -- Remogliflozin etabonate; Bioorganic chemistry -- Periodicals; Pharmaceutical chemistry -- Periodicals; Biochemistry -- Periodicals; Chemistry, Clinical -- Periodicals; Chemistry, Organic -- Periodicals; Chimie bio-organique -- Périodiques; Chimie pharmaceutique -- Périodiques; 615.19
• DOI: 10.1016/j.bmc.2021.116033
• Languages: English
• ISSNs: 0968-0896

Abstract

Graphical abstract: Abstract: We optimized the structure of an active metabolite (1) of WAY-123783, which was obtained from mouse urine after oral administration, to improve selectivity for SGLT2 and oral bioavailability. O -glucoside derivative 24 (remogliflozin etabonate) was subsequently identified as a potent, highly selective, and orally available SGLT2 inhibitor.